Stock Analysis on Net

Abbott Laboratories (NYSE:ABT)

$24.99

Return on Equity (ROE)
since 2005

Microsoft Excel

Paying user area

The data is hidden behind: . Unhide it.

This is a one-time payment. There is no automatic renewal.


We accept:

Visa Mastercard American Express Maestro Discover JCB PayPal Google Pay
Visa Secure Mastercard Identity Check American Express SafeKey

Calculation

Abbott Laboratories, ROE, long-term trends, calculation

Microsoft Excel

Based on: 10-K (reporting date: 2025-12-31), 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31), 10-K (reporting date: 2014-12-31), 10-K (reporting date: 2013-12-31), 10-K (reporting date: 2012-12-31), 10-K (reporting date: 2011-12-31), 10-K (reporting date: 2010-12-31), 10-K (reporting date: 2009-12-31), 10-K (reporting date: 2008-12-31), 10-K (reporting date: 2007-12-31), 10-K (reporting date: 2006-12-31), 10-K (reporting date: 2005-12-31).

1 US$ in millions


The return on equity (ROE) for the period between 2005 and 2025 demonstrates considerable fluctuation. Initial values are strong, followed by periods of decline, recovery, and ultimately, significant volatility. A general observation is that ROE is sensitive to changes in both net earnings and total shareholders’ investment.

Initial Period (2005-2008)
ROE began at 23.39% in 2005, decreased substantially to 12.22% in 2006, then recovered to 20.28% in 2007. A notable increase occurred in 2008, reaching 27.92%, suggesting improved profitability relative to shareholder equity during that year.
Period of Stability and Decline (2009-2011)
Following 2008, ROE remained relatively high at 25.14% in 2009, but then experienced a gradual decline to 19.35% by 2011. This suggests that while profitability remained positive, it did not keep pace with growth in shareholder equity.
Moderate Fluctuations (2012-2016)
The period from 2012 to 2016 exhibited moderate fluctuations. ROE increased to 22.32% in 2012, then decreased significantly to 10.23% in 2013, followed by a slight recovery to 10.61% in 2014. A substantial increase to 20.85% occurred in 2015, but was followed by a sharp decline to 6.82% in 2016. This period highlights the impact of earnings volatility on ROE.
Significant Volatility and Peak (2017-2023)
From 2017 through 2023, ROE experienced significant volatility. It dropped to a low of 1.54% in 2017, then increased to 7.76% in 2018, 11.86% in 2019, and 13.71% in 2020. A substantial increase was observed in 2021, reaching 19.75%, followed by 18.90% in 2022. However, ROE decreased to 14.83% in 2023.
Recent Performance (2024-2025)
A significant peak in ROE occurred in 2024, reaching 28.12%, representing the highest value in the analyzed period. This was followed by a decrease to 12.51% in 2025. This recent volatility suggests a potential shift in the company’s profitability or capital structure.

Overall, the ROE demonstrates a pattern of cyclicality and sensitivity to changes in net earnings and shareholder investment. The substantial increase in 2024, followed by a decrease in 2025, warrants further investigation to determine the underlying drivers of these changes.


Comparison to Competitors

Abbott Laboratories, ROE, long-term trends, comparison to competitors

Microsoft Excel

Based on: 10-K (reporting date: 2025-12-31), 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31), 10-K (reporting date: 2014-12-31), 10-K (reporting date: 2013-12-31), 10-K (reporting date: 2012-12-31), 10-K (reporting date: 2011-12-31), 10-K (reporting date: 2010-12-31), 10-K (reporting date: 2009-12-31), 10-K (reporting date: 2008-12-31), 10-K (reporting date: 2007-12-31), 10-K (reporting date: 2006-12-31), 10-K (reporting date: 2005-12-31).


Comparison to Sector (Health Care Equipment & Services)

Abbott Laboratories, ROE, long-term trends, comparison to sector (health care equipment & services)

Microsoft Excel

Based on: 10-K (reporting date: 2025-12-31), 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31), 10-K (reporting date: 2014-12-31), 10-K (reporting date: 2013-12-31), 10-K (reporting date: 2012-12-31), 10-K (reporting date: 2011-12-31), 10-K (reporting date: 2010-12-31), 10-K (reporting date: 2009-12-31), 10-K (reporting date: 2008-12-31), 10-K (reporting date: 2007-12-31), 10-K (reporting date: 2006-12-31), 10-K (reporting date: 2005-12-31).


Comparison to Industry (Health Care)